Tag: Covid

Categories
Health

Black well being leaders attempt to construct belief within the Covid vaccine amongst African People

Black health leaders try to build trust in the Covid vaccine among African Americans

A researcher works at a laboratory operated by Moderna Inc that said in an undated still image from a video on November 16, 2020 that his experimental vaccine was 94.5% effective in preventing COVID-19, based on interim data from one late clinical trial.

Modern | via Reuters

Dr. Lou Edje participated in the Moderna vaccine study in her healthcare system in Cincinnati, Ohio after three of her relatives died from the coronavirus earlier this year. This led her to do more to instill trust in her community and get vaccinated.

“I felt like I might be able to make a believable impact on the patients I care for every day who look just like me,” said Edje, Black and Associate Dean for Medical Education at the University of Cincinnati College of Medicine.

Although she wasn’t told if she received the actual vaccine during the trial, she had a slight swelling in her arm after the booster shot – which leads her to believe she did. This helps when patients ask what to expect.

“Some of the side effects were a little more robust the second time around, so I’m trying to tell them exactly what I went through,” she explained.

It can take months before the public are vaccinated with new vaccines once they are approved. The Food and Drug Administration is expected to quickly clear Pfizer’s vaccine for emergency use after an advisory panel overwhelmingly approved the shots on Thursday. Starting doses have been set for frontline health workers and the elderly in long-term care facilities such as nursing homes.

Still, African-American health professionals and community health groups across the country have already started reaching out in black communities hard hit by the coronavirus. According to a poll by Pew Research last month, seven out of ten African Americans know someone who was hospitalized or died of Covid. However, there is great skepticism about vaccines. Only 42% of blacks surveyed say they have been vaccinated, compared with more than 60% of Americans as a whole.

“They want to know, and have real reasons to trust. They want to know that the trial will be fair, that they are not guinea pigs for a system that is turned against them,” explained Dr. Reed Tuckson, co-founder of the Black Coalition Against Covid and former Washington, DC Commissioner for Health

The speed at which the Covid vaccine was being developed was one of the issues that many Americans have concerns about being in the first wave to get the shot. But for African Americans, the skepticism is also based in part on history. As part of the infamous Tuskegee study of syphilis, African American men were treated with placebo drugs instead of antibiotics, which they could cure, so officials could follow the disease over the years.

The Coalition on Covid has brought together major African American medical groups, including the National Medical Association and the National Black Nurses Association, as well as heads of four historically black medical schools, including Howard University and Morehouse College, to advocate for African American patients.

In the clinical arena, they have urged federal and local government officials to prioritize access for color communities where the prevalence of pre-existing conditions like high blood pressure and diabetes has increased people’s vulnerability to the virus.

“We shouldn’t let the proliferation of a life-saving vaccine worsen health inequalities. In fact, it should help narrow them down,” said Tuckson.

In terms of reach, they’ve held a number of informative town halls online with government leaders including Dr. Anthony Fauci, the country’s foremost infectious disease expert, to address specific concerns among African Americans.

They also work with community health groups, local churches, and stakeholders who can reach out to the grassroots personally from a place of trust.

“Fifty percent of one neighborhood must have the vaccine to burn out the virus in the other 50 percent,” explained Edje. “We really need to ensure that every neighborhood has some immunity so that we can make a global impact.”

The fact that it will take time for the public to gain access to the vaccine could prove to be a silver lining. Health officials say it will show people how the first wave of those who get the shot react, which can help fight skepticism and fear.

Categories
World News

White Home threatens to fireplace FDA chief until Covid vaccine OKed Friday: experiences

White House threatens to fire FDA chief unless Covid vaccine OKed Friday: reports

US President Donald Trump and Stephen Hahn, Director of the Food and Drug Administration, attend the daily meeting of the coronavirus task force at the White House in Washington, DC on April 24, 2020.

Drew Angerer | Getty Images

White House chief of staff, Mark Meadows, has urged the head of the Food and Drug Administration to resign if the agency does not clear Pfizer’s coronavirus vaccine for emergency use by the end of the day, the Washington Post reported on Friday.

The warning prompted FDA Commissioner Stephen Hahn and the agency to accelerate their schedule for the release of America’s first Covid-19 vaccine from Saturday morning to late Friday, according to the Post, citing anonymous sources.

The New York Times, Axios, and Reuters also reported that Meadows urged Hahn to resign if he wasn’t quick enough to remove the vaccine.

In a statement, Hahn called the Post’s report “an untrue account”.

“This is an untrue representation of the telephone conversation with the chief of staff,” Hahn told CNBC on Friday afternoon. “The FDA has been encouraged to continue working swiftly on Pfizer-BioNTech’s EEA request. The FDA is committed to swiftly granting this approval, as we noted in our statement this morning.”

The White House did not immediately respond to CNBC’s request for comment.

The reports come a day after a key FDA advisory body voted 17-4, with one abstention, to recommend the vaccine, which Pfizer partnered with BioNTech, for emergency approval. The FDA typically follows the recommendations of the Advisory Committee on Vaccines and Related Biological Products. After the overwhelming vote, the FDA should release the vaccine on Friday.

Hahn said earlier that day the agency was “working fast” to clear Pfizer’s emergency vaccine. “The agency has also notified the US Centers for Disease Control, Prevention and Operation Warp Speed ​​so they can implement their plans for timely vaccine distribution,” Hahn said in a joint statement with Dr. Peter Marks, director of the FDA Center for Biologics Evaluation and Research.

Shortly after Hahn ’s remarks, President Donald Trump, who has repeatedly urged the FDA to speed up the vaccine development process, tweeted the agency,” Get the dam vaccines out NOW. “

“Stop playing and save lives !!!”

FDA approval would mark a record-breaking timeframe for a process that typically takes about a decade. The fastest vaccine development to date against mumps took more than four years and was licensed in 1967. Pfizer and BioNTech announced plans to develop a coronavirus vaccine in March and filed an emergency clearance application with the FDA in November.

An emergency permit, or EEA, is not the same as a full permit, which can typically take months. Pfizer has only submitted safety data for two months, but it typically takes the agency six months for full approval.

– CNBC’s Amanda Macias contributed to this report.

Categories
Business

Pfizer’s Covid Vaccine and Allergic reactions: How Involved Ought to You Be?

Pfizer's Covid Vaccine and Allergies: How Concerned Should You Be?

Dr. Fauci acknowledged that the problem could affect many people.

“That’s one of the reasons it’s important to cover the waterfront with different vaccine platforms,” ​​he said, adding, “When we actually find out that there is a consistent problem with a certain subset of people like people with allergic reactions, You will always have other vaccine platforms to use and hopefully you won’t see that with those other platforms. “

Dr. Paul Offit, a vaccines expert at Philadelphia Children’s Hospital, said the initial, sweeping recommendation in the UK to mention severe allergic reactions was an overreaction that could unnecessarily discourage many people from a much-needed vaccine in the midst of a raging pandemic.

Millions of people in the United States are allergic to foods such as eggs or peanuts, as well as drugs or bee stings, and have had reactions so severe that doctors advised them to wear adrenaline injectors. But that doesn’t necessarily mean the vaccine is risky for them, he said. According to the National Institute of Allergy and Infectious Diseases, about five percent of children and four percent of adults in the United States have food allergies.

Less than 1 in a million recipients of other vaccines each year in the U.S. has an anaphylactic reaction, said Dr. Offit.

These reactions are treatable and much easier to control than a severe case of Covid-19, he said.

Many people with allergies to food, bee stings, or medication have received multiple vaccines without any problems.

The road to a coronavirus vaccine ›

Answers to your vaccine questions

As the coronavirus vaccine nears U.S. approval, here are some questions you may be wondering about:

    • If I live in the US, when can I get the vaccine? While the exact order of vaccine recipients may vary from state to state, most doctors and residents of long-term care facilities will come first. If you want to understand how this decision is made, this article will help.
    • When can I get back to normal life after the vaccination? Life will only get back to normal once society as a whole receives adequate protection against the coronavirus. Once countries have approved a vaccine, they can only vaccinate a few percent of their citizens in the first few months. The unvaccinated majority remain susceptible to infection. A growing number of coronavirus vaccines show robust protection against disease. However, it is also possible that people spread the virus without knowing they are infected because they have mild symptoms or no symptoms at all. Scientists don’t yet know whether the vaccines will also block the transmission of the coronavirus. Even vaccinated people have to wear masks for the time being, avoid the crowds indoors and so on. Once enough people are vaccinated, it becomes very difficult for the coronavirus to find people at risk to become infected. Depending on how quickly we as a society achieve this goal, life could approach a normal state in autumn 2021.
    • Do I still have to wear a mask after the vaccination? Yeah, but not forever. The two vaccines that may be approved this month clearly protect people from contracting Covid-19. However, the clinical trials that produced these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected with the coronavirus can spread it without experiencing a cough or other symptoms. Researchers will study this question intensively when the vaccines are introduced. In the meantime, self-vaccinated people need to think of themselves as potential spreaders.
    • Will it hurt What are the side effects? The vaccine against Pfizer and BioNTech, like other typical vaccines, is delivered as a shot in the arm. The injection is no different from the ones you received before. Tens of thousands of people have already received the vaccines, and none of them have reported serious health problems. However, some of them have experienced short-lived symptoms, including pain and flu-like symptoms that usually last a day. It is possible that people will have to plan to take a day off or go to school after the second shot. While these experiences are not pleasant, they are a good sign: they are the result of your own immune system’s encounter with the vaccine and a strong response that ensures lasting immunity.
    • Will mRNA vaccines change my genes? No. Moderna and Pfizer vaccines use a genetic molecule to boost the immune system. This molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse with a cell, allowing the molecule to slide inside. The cell uses the mRNA to make proteins from the coronavirus that can stimulate the immune system. At any given moment, each of our cells can contain hundreds of thousands of mRNA molecules that they produce to make their own proteins. As soon as these proteins are made, our cells use special enzymes to break down the mRNA. The mRNA molecules that our cells make can only survive a few minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a little longer, so the cells can make extra viral proteins and trigger a stronger immune response. However, the mRNA can hold for a few days at most before it is destroyed.

As a member of the FDA advisory board that met on Thursday, Dr. Offit for approval of the Pfizer vaccine. However, during the panel’s discussion of allergic reactions, he said, “This problem will not die until we have better data.”

He said it should investigate whether any ingredient in the vaccine can cause allergic reactions and whether people with other allergies might be particularly sensitive to it.

Categories
Health

Dr. Fauci says Covid vaccine trials on pregnant ladies and younger children might start in January

Dr. Fauci says Covid vaccine trials on pregnant women and young kids could begin in January

Drug makers and U.S. regulators plan to start clinical trials in January testing the safety of Covid-19 vaccines in pregnant women and young children, said Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases.

These two groups were excluded from the initial clinical trials of Covid-19 vaccines until researchers were able to determine that the vaccine was relatively safe in healthy adults before testing in more susceptible populations.

Fauci noted on Thursday in a discussion sponsored by Columbia University on Thursday that pregnant women have not been included in clinical trials of Covid vaccines. It is not clear whether the omission means that pregnant women cannot receive an approved vaccine until further safety data are collected.

Studies on pregnant women will be done in later studies, he said.

“It won’t necessarily concern efficacy, but we will be investigating safety and immunogenicity to bridge efficacy in the adult non-pregnant population,” he said at Columbia University’s Grand Rounds 2020 event. “The same goes for the pediatric population. These studies are expected to begin in mid-to-late January.”

Doctors have noted an increased risk of complications in pregnant women who contract Covid-19, said Aron Hall, chief of Covid at the CDC.

“The first indication is that there may be a higher risk of premature delivery,” he said Thursday on the FDA’s Advisory Committee on Vaccines and Related Biological Products.

While young children are less likely to die of Covid-19 when they get it, there is an increased risk of developing what is known as multisystem inflammatory syndrome in children, or MIS-C, researchers have found. It is an inflammatory disease that can affect several organ systems throughout the body, including the heart, lungs, and brain.

Fauci’s comments came as the FDA’s Vaccine Advisory Board is weighing whether to recommend Pfizer’s emergency approval of the Covid vaccine.

Data on Pfizer’s vaccine has shown it to be remarkably effective in preventing disease among study participants, and the FDA is expected to approve emergency use as early as Friday.

The UK drug and health products regulator, which last week approved Pfizer’s vaccine for wide use in adults, warned against giving it to pregnant or breastfeeding women.

Dr. Doran Fink, associate director of the FDA’s vaccines and related products division, said Thursday there was “very limited data on use in pregnancy”.

“We recognize that among the groups first prioritized for vaccine use under an EEA, there will be many women of childbearing potential, including women who are knowingly or unknowingly pregnant,” he said on the Meet on Thursday afternoon. “We really do not have any data that suggest any specific risks to pregnant women or the fetus, but neither do we have any data that would justify a contraindication to use in pregnancy at this time.”

He added that pregnant women and women of childbearing age are “free to make their own choice” under what is known as an emergency permit.

The FDA advised manufacturers, including Pfizer, to conduct DART studies or developmental and reproductive toxicity studies before including pregnant women and “women of childbearing potential who do not actively avoid pregnancy” in vaccine studies, Pfizer said – Speaker Jerica Pitts CNBC. DART studies are done in animals to assess the potential risks of a vaccine to a developing fetus.

“Pfizer recognizes that the development of a potential SARS-CoV-2 vaccine for wide use is critical to halting the pandemic, including potential use in pregnant women,” Pitts said in a statement. “Pfizer is currently conducting DART studies and plans to provide available data to the agency.”

Pfizer admitted at the FDA’s vaccine meeting Thursday that according to a presentation there was no information about the effects of the vaccine on pregnant women. Company officials told the advisory board that they expected preliminary results from its DART studies by mid-December.

The company also noted that there is also a lack of information on the effects of the vaccine in children and adolescents under the age of 16. The FDA advisory panel will vote on its non-binding recommendation later Thursday, and the FDA is expected to do so soon.

– CNBC’s Amanda Macias contributed to this report.

Categories
Business

Covid pandemic drove a file drop in international carbon emissions in 2020

Covid pandemic drove a record drop in global carbon emissions in 2020

The empty Champs Elysees avenue is pictured in Paris, France on March 28, 2020. The country has fined people who violate its statewide lockdown measures to stop the spread of COVID-19.

Pascal Le Segretain | Getty Images

Global greenhouse gas emissions have decreased by around 2.4 billion tons this year, a 7% decrease from 2019 and the largest decrease in history triggered by global Covid-19 restrictions. This is the result of new research from the University of East Anglia, the University of Exeter and the University of East Anglia, the Global Carbon Project.

The researchers said carbon emissions are likely to rise again in 2021, and urged governments to prioritize a shift to clean energy and action to combat climate change in their recovery plans.

Daily global carbon emissions fell 17% during the peak of the pandemic lockdowns in April, but have since risen again, approaching 2019 levels, according to the report published Thursday in Earth System Science Data.

“All the elements to sustainably reduce global emissions are not yet in place, and emissions are slowly falling back to 2019 levels,” Corinne Le Quere, professor at the UEA’s School of Environmental Sciences, said in a statement.

“Government action to stimulate the economy at the end of the Covid-19 pandemic can also help cut emissions and combat climate change,” she added.

The US saw the largest drop in CO2 emissions at 12%, followed by the European Union at 11%, the report said. In both cases, pandemic restrictions accelerated the decline in the use of coal in power generation and oil in transportation.

In developing countries, CO2 emissions fell by 9% in India, but only by 1.7% in China. China’s lockdown took place earlier in the year and was shorter in duration. In addition to the country’s rising CO2 emissions, there have been restrictions on CO2 emissions.

A decline in transport activity led to a global decrease in CO2 emissions. Emissions from automobiles and air travel fell by about half during the peak of Covid restrictions in April, and by December they were down about 10% and 40%, respectively, from 2019, according to the report.

More of CNBC environment::
A historic Atlantic hurricane season is coming to an end. Here’s a look at the records it broke
Biden will rejoin the Paris Climate Agreement. Here’s what happens next
“We’re Running Out of Time”: Destructive Colorado wildfires get worse as the season worsens

“Incentives that help accelerate the use of electric cars and renewables and encourage walking and cycling in cities are particularly timely given the significant disruption seen in the transport sector this year,” said Le Quere.

The historical decline in global emissions has also had a negligible impact on the levels of carbon in the atmosphere, which are warming the earth and worsening climate catastrophes, melting ice, and rising sea levels.

In 2020 alone, forest fires caused by climate change burned a record amount of land in the western United States, and the most active hurricane season in the Atlantic ravaged Central America and the Gulf Coast states.

“The climate system is powered by the total amount of CO2 that has been released into the atmosphere over centuries,” said Glen Peters, Research Director of International Climate Research in Norway and a member of the Global Carbon Project.

“Although emissions decreased in 2020, they were still at 2012 levels and the decrease is insignificant compared to the total amount of CO2 emitted over the past few centuries,” he said.

While global carbon emissions have steadily increased over the past few decades, researchers have found that emissions growth has increased more slowly in recent years, mainly due to changes in coal production.

“Global warming stops when emissions go to zero and Covid-19 hasn’t changed that,” Peters said.

Categories
Health

F.D.A. Panel Provides Inexperienced Mild to Pfizer’s Covid Vaccine

F.D.A. Panel Gives Green Light to Pfizer's Covid Vaccine

Pfizer’s Covid-19 vaccine passed a critical milestone on Thursday when a panel of experts formally recommended that the Food and Drug Administration authorize the vaccine. The agency is likely to do so within days, giving health care workers and nursing home residents first priority to begin receiving the first shots early next week.

The F.D.A.’s vaccine advisory panel, composed of independent scientific experts, infectious disease doctors and statisticians, voted 17 to 4, with one member abstaining, in favor of emergency authorization for people 16 and older. With rare exceptions, the F.D.A. follows the advice of its advisory panels.

With this formal blessing, the nation may finally begin to slow the spread of the virus just as infections and deaths surge, reaching a record of more than 3,000 daily deaths on Wednesday. The F.D.A. is expected to grant an emergency use authorization on Saturday, according to people familiar with the agency’s planning, though they cautioned that last-minute legal or bureaucratic requirements could push the announcement to Sunday or later.

The initial shipment of 6.4 million doses will leave warehouses within 24 hours of being cleared by the F.D.A., according to federal officials. About half of those doses will be sent across the country, and the other half will be reserved for the initial recipients to receive their second dose about three weeks later.

The arrival of the first vaccines is the beginning of a complex, monthslong distribution plan coordinated by federal and local health authorities, as well as large hospitals and pharmacy chains, that if successful, will help return a grieving and economically depressed country back to some semblance of normal, maybe by summer.

“With the high efficacy and good safety profile shown for our vaccine, and the pandemic essentially out of control, vaccine introduction is an urgent need,” Kathrin Jansen, a senior vice president and the head of vaccine research and development at Pfizer, said at the meeting.

The vote caps a whirlwind year for Pfizer and its German partner BioNTech, which began working on the vaccine 11 months ago, shattering all speed records for vaccine development, which typically takes years. It is also a triumph for the F.D.A., which has upheld its reputation as the world’s gold standard for drug reviews despite months of political pressure from President Trump, who has sought to tie his political fortunes to the success of a vaccine. The Pfizer vaccine has already been given to people in Bahrain and Britain, where it was authorized on Dec. 2. Canada approved it on Wednesday.

The U.S. authorization of Pfizer’s vaccine is expected to be followed soon by one for Moderna’s version, which uses similar technology and has also shown promising results in clinical trials. Operation Warp Speed, the Trump administration’s multi-billion-dollar program to fast-track vaccine development, pre-ordered 100 million doses of Pfizer’s vaccine in July and heavily backed the development and manufacturing of Moderna’s vaccine.

More than 100 F.D.A. employees have worked nearly round the clock to review the application Pfizer submitted on Nov. 20, compressing months of analysis into weeks as they pored over thousands of pages of clinical trial and manufacturing data.

Earlier this week, career scientists at the F.D.A. published an analysis showing the vaccine worked across a variety of demographic groups and that it was somewhat effective even after the first of two doses.

During the daylong meeting on Thursday, panel members peppered company and agency experts with detailed questions about the safety and efficacy of the vaccine, which was found to be 95 percent effective in a late-stage clinical trial. Some members expressed concern that there was not enough data from 16- and 17-year-olds to know whether the vaccine would help them, but the committee decided the benefits for that group outweighed the risks.

Some members asked about the likelihood for serious allergic reactions, given the news that regulators in Britain recommended this week that people with a history of anaphylactic allergic reactions to medicines and foods not get the vaccine while they investigate two cases of allergic reactions among health care workers. Pfizer officials said there were no cases of serious allergic reactions in the trial of 44,000 participants. People with a history of allergic reactions to vaccines were excluded from the study.

One of the panel members, Dr. Paul Offit of the Children’s Hospital of Philadelphia, said he feared that statements by British regulators as well as remarks by Moncef Slaoui, a top U.S. vaccine official, could lead “tens of millions” of people with severe allergies to reject the vaccine even though evidence of a link to the shots was unclear. He asked Pfizer to conduct a separate study of people with a history of severe allergies, because “this issue is not going to die until we have better data.”

The F.D.A. said that it had asked Pfizer to include allergic reactions in its safety tracking plan and would include a warning in its instructions on the use of the vaccine.

One of the most hotly contested issues was how the broad authorization of the vaccine might affect the continuing clinical trial. Some experts have argued that, ethically, trial volunteers who received a placebo should be offered the vaccine once it is authorized, but others worried that move could tarnish the long-term results of the trial.

During the public portion of the meeting, consumer and public health advocates largely pushed the agency to authorize the vaccine, noting the urgency of the pandemic. One speaker, who identified himself as Kermit Kubitz, noted that he had no conflicts of interest to declare except for “a lot of elderly relatives.”

“They need this vaccine yesterday,” he said.

But advocates also asked regulators to be transparent about potential safety issues and to closely track the vaccine once it becomes available. Several said such measures were necessary to reassure a public that is hesitant to take a new vaccine, particularly Black and Native American people who have historically been mistreated by the medical community. “Before authorization is granted, affected communities need to have confidence that the vaccine is safe and effective,” said Sarah Christopherson of the National Women’s Health Center.

By insisting that the advisory committee vote on any vaccine, regulators created a shield against White House pressure to approve a product before the presidential election. When the panelists met in October to discuss the F.D.A.’s guidelines for approving Covid-19 vaccines, they urged the agency to take its time and cautioned that rushing the process could risk missing vital safety data and further erode public trust.

The scene that played out on Thursday — in which outside experts spent hours engaging government officials in an intense but often highly technical discussion about vaccine science — did not always make for exciting viewing. But the circumstances were certainly dramatic, as the experts were being asked to carefully weigh the risks and benefits of the vaccine, even as the United States reached the grim milestone of recording more than 3,000 Covid deaths on Wednesday and as thousands of people in Britain had already received it.

The F.D.A. has struggled, internally and externally, to move fast on its vaccine and treatment deliberations in order to curb the deadly virus’s spread — but not so fast as to undermine public confidence. It was a thin line to walk, and not helped by the torrent of troubling accusations by Mr. Trump and his advisers that the agency was moving too slowly.

Just days before Pfizer submitted its application, the company sent an enormous tranche of manufacturing data to the F.D.A. — including materials on how it was scaling up production — leaving regulators scrambling to evaluate it in time for a possible authorization.

As part of its oversight, the F.D.A. also had teams review company production facilities and clinical trial sites, where they verified that records corresponded to the accounts Pfizer had submitted to federal regulators.

At the same time, regulators were evaluating an equally complex emergency authorization application submitted by Moderna, whose data will be examined publicly during another F.D.A. outside advisory meeting next week.

The Road to a Coronavirus Vaccine ›

Answers to Your Vaccine Questions

As the coronavirus vaccine get closer to U.S. authorization, here are some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. The two vaccines that will potentially get authorized this month clearly protect people from getting sick with Covid-19. But the clinical trials that delivered these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected by the coronavirus can spread it while they’re not experiencing any cough or other symptoms. Researchers will be intensely studying this question as the vaccines roll out. In the meantime, even vaccinated people will need to think of themselves as possible spreaders.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection won’t be any different from ones you’ve gotten before. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. But some of them have felt short-lived discomfort, including aches and flu-like symptoms that typically last a day. It’s possible that people may need to plan to take a day off work or school after the second shot. While these experiences aren’t pleasant, they are a good sign: they are the result of your own immune system encountering the vaccine and mounting a potent response that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

Regulators sometimes received documents from the companies as late as midnight and worked through the Thanksgiving holiday. Dr. Peter Marks, the top vaccine regulator at the F.D.A., joked last week at an event hosted by the American Medical Association that his team ate turkey sandwiches while examining documents.

“Among all global regulators, we are the ones that actually don’t just look at the company’s tables. We actually get down and dirty and we look at the actual adverse event reports, the bad spelling errors that are made by physicians sometimes, et cetera,” he said at the event.

Dr. Stephen M. Hahn, the F.D.A. commissioner, kept a careful distance from the review, according to people familiar with it.

Dr. Hahn had caved to pressure earlier in the summer to authorize an old malaria drug, hydroxychloroquine, for use in Covid patients even though there was little evidence that it worked. That decision was reversed after the agency found the drug was unlikely to be effective in Covid patients and carried a risk of potentially dangerous side effects. And Dr. Hahn faced withering criticism from the scientific community after he exaggerated the benefits of another treatment, convalescent plasma, an error he later corrected.

Mr. Trump accused agency officials of being part of the “deep state” and hinted that a vaccine could come before “a very special day” — Election Day. The F.D.A.’s reputation appeared to be headed in the same direction as that of the Centers for Disease Control and Prevention, which was widely criticized for not standing up to the president.

But senior regulators — and eventually Dr. Hahn himself — pushed back. The agency’s top career officials published an opinion piece in USA Today, acknowledging that the F.D.A.’s integrity had been called into question and insisting that they would “follow the science” during the pandemic. The agency prevailed in a battle with the White House over imposing more stringent guidelines for companies developing Covid vaccines.

“In this sort of environment, where there has been so much pressure and concern, the process does provide an important check and balance,” said Dr. Jesse L. Goodman, who previously served as the F.D.A.’s chief scientist. Holding an open meeting also allows the public to “be sure that a broader scientific and clinical community is comfortable with the decision.”

On Tuesday, the president held a summit intended to showcase the administration’s role in developing a vaccine. “We are just days away from authorization from the F.D.A. and we’re pushing them hard,” Mr. Trump said at the event.

Many health care workers around the country are already raring to get the vaccine. Dr. Andrew Barros, a critical care physician in Charlottesville, Virginia, who is scheduled to get his Pfizer shot at 2:30 p.m. on Dec. 15, said he is “looking forward to having a sore arm and hopefully being one step closer to having Covid under control.”

Pfizer’s clinical trial will continue even after its vaccine is authorized by the F.D.A., and the company and F.D.A. will continue to watch for safety concerns.

Pfizer said on Thursday that it planned to apply for full approval in April of 2021, after the company had collected six months of safety data. At that point, Pfizer would be allowed to sell its vaccine directly to hospitals and other health care providers.

Carl Zimmer and Katherine J. Wu contributed reporting.

Categories
Business

Reside Market Updates: Shares Decline Amid Covid Restrictions and Rising Instances

Goods are piling up at some British ports, as trucks and rail have failed to keep up with companies trying to stockpile ahead of Brexit.

Here’s what you need to know:

Credit…Andrew Testa for The New York Times

Businesses in Britain and the European Union are bracing for the economic disruption of Brexit, which threatens to clog ports and disrupt trade across the English Channel on Dec. 31 if leaders do not reach a compromise to settle their future trading relationship.

But the economic breakup could have a relatively limited impact on trade with the United States, trade experts said.

Because the United States does not have a free-trade agreement with the European Union, Britain’s departure from the bloc will do little to alter its trading relationship with the United States. Following Brexit, the terms of trade between the United States and Britain will continue to be governed by the rules of the World Trade Organization, as they were before.

The direct effect on the two trade partners “should be minimal given there’s no change in tariffs,” said Christopher Rogers, a global trade and logistics analyst at Panjiva.

Still, he said, significant customs disruptions between Europe and Britain could have knock-on effects for supply chains, if, for example, it takes British businesses that are exporting to the United States longer to source components from abroad. Goods are piling up at some British ports, as trucks and rail have failed to keep up with companies trying to stockpile ahead of Brexit.

Britain’s trading terms with the United States may not get much worse, but they also appear unlikely to get better.

The two countries have been carrying out negotiations for a free-trade deal since May. But with the election of Joseph R. Biden Jr., the prospects for that agreement, which many Britons saw as a source of post-Brexit strength, have been greatly diminished.

The congressional authority that gives trade deals an easier path to approval by Congress, called trade promotion authority, is set to expire this summer, and Mr. Biden has promised not to enter into any major new trade agreements until the United States has made major investments at home.

Boeing 737 Max aircraft in a lot at Boeing Field in Seattle. The plane was grounded worldwide almost two years ago.Credit…Lindsey Wasson/Reuters

Gol Airlines, a Brazilian carrier, said it planned to start flights aboard the Boeing 737 Max on Wednesday, making it the first airline to fly passengers on the plane since it was grounded worldwide almost two years ago.

The first flights will be on domestic routes to and from Gol’s hub in São Paulo, with the company expecting all seven of the Max planes in its fleet to be updated and cleared to fly by the end of the month. A Gol spokeswoman declined to provide further details.

“Our first priority is always the safety of our customers,” Celso Ferrer, vice president of operations and a commercial pilot at Gol, said in a statement. “Over the past 20 months, we have watched the most comprehensive safety review in the history of commercial aviation unfold.”

The Max was banned worldwide in March 2019 after a total of 346 people were killed in two crashes aboard the plane. In the United States, the Federal Aviation Administration last month became the first regulator to allow the plane to fly again, after required modifications are made. The agency was recently joined by regulators in Brazil, while the European aviation authority has suggested that it plans to lift its ban within weeks. Relatives of those killed in the crashes criticized the decision to allow the plane to fly again, arguing that it remains unsafe.

The lifting of the ban allows Boeing to restart sales and deliveries in earnest after its passenger airline business was pummeled by the grounding and the pandemic. The plane maker on Tuesday reported a net decline of 61 orders last month. Boeing’s backlog of orders, most of them for the Max, stood at 4,240, down more than a thousand from the start of the year after accounting for fulfilled orders.

Still, airlines are still interested in acquiring the plane. Last week, the company announced it had agreed to sell 75 Max jets to Ryanair, the low-cost European airline. Like RyanAir, Gol is among the biggest customers for the Max. The airline’s fleet is composed of 127 Boeing planes and it has an order for 95 Max jets scheduled for delivery over a decade starting in 2022.

Brian Chesky, Airbnb’s co-founder, in 2018. It’s usually not regular people, employees or even pre-I.P.O. investors who get a windfall from initial public offerings.Credit…Eric Risberg/Associated Press

A dirty secret of initial public offerings is that even the coolest ones may make only a handful of people rich — and it may not be regular people, employees or even fancy pre-I.P.O. investors who get a windfall.

DoorDash and Airbnb are expected to have spectacular first sales on public stock exchanges this week and start trading at far higher levels than anticipated even a few weeks ago.

But buying stock in relatively young and unproven companies — which usually describes technology companies selling their stock to the public for the first time — is often a coin-toss bet. Even the professional investors who buy stock in hot companies before they go public don’t always get rich, unless they throw their money around early and get lucky. Companies you might have heard of like Uber, Lyft, Snapchat and Slack were at best meh I.P.O. investments.

Look at Airbnb. Among the investors who got a special chance to buy Airbnb stock nearly four years ago, each $10,000 of stock they bought will be worth about $11,500 if Airbnb starts selling its shares to the public for $60 each. Nice!

But if your aunt had invested $10,000 nearly four years ago in a simple fund that mirrored the ups and downs of the S&P 500 stock index, she would now have $15,600. Even nicer.

The pandemic hurt business for Uber and Lyft, but their stocks were losers before then. Uber’s stock price has bounced back and is now up 30 percent since the spring, and still anyone who bought Uber shares in its 2019 I.P.O. — and even the professional investors who bought its stock in the four years before that — would have made far more money buying an index fund. Uber employees who were hired before the I.P.O. and were paid partly in stock also would have been better off getting paid in an index fund.

People who bought Snapchat’s stock in its 2017 initial public offering had to wait more than three years to not lose money on their bet. Slack just sold itself at a share price not much higher than its first public stock sale last year.

These are cherry-picked examples. There are companies whose stock prices have soared since their I.P.O.s and made people rich — Zoom Video is a prominent example in technology. And the people who have already bet on the restaurant delivery app DoorDash stand to make a big profit when the company goes public this week.

Will Airbnb be a winning I.P.O.? It depends. It definitely will be for the venture capital firm Sequoia, which bet on Airbnb early. And it’s certainly faring better than people expected when travel froze early this year. But no one can confidently predict whether its share price will shoot to the moon like Zoom’s has since its 2019 I.P.O. or will plunge as Lyft’s did after it went public.

That’s the lesson. Cool companies don’t always make good investments. The people screaming on Robinhood about their splurge on a hot I.P.O. may not know what they’re talking about.

By: Ella Koeze·Source: Refinitiv

  • Stocks were unsteady on Tuesday, as the spread of coronavirus cases and restrictions on people’s movement and businesses outweighed optimism about the rollout of a vaccine.

  • The S&P 500 was flat by midday after recovering from an earlier dip. The Stoxx Europe 600 and Britain’s FTSE 100 also recouped small losses and were slightly higher.

  • In the United States, rising numbers of virus cases has led California to impose new stay-at-home orders in large swathes of the state. In New York, the number of people hospitalized with the coronavirus is rising and could lead to another ban on indoor dining.

  • In Europe, countries are struggling to emerge from a second wave of the pandemic. The infection rate in France is threatening plans to ease restrictions before the holidays, and in Greece, the lockdown was extended until early January.

  • But on a brighter note, Britain on Tuesday started a mass vaccination campaign, delivering the first shots of the Pfizer-BioNTech Covid-19 vaccine. “There is finally some clear light at the end of a very dark tunnel,” James Pomeroy, an economist at HSBC, wrote in a note to clients. “And that cheer should be seen in some of the economic data in the coming year too.”

  • Tesla said on Tuesday it would sell as much as $5 billion in shares, its third return to markets in 10 months, and use the money for more investments including factory construction. Tesla’s shares were down nearly 3 percent. This year, the electric carmaker’s shares have risen about 670 percent, and later this month, the company will join the S&P 500.

Google’s offices in London. Britain’s top antitrust regulator recommended a new tech watchdog.Credit…Ben Stansall/Agence France-Presse — Getty Images

Governments around the world have been grappling with ways to crimp the power of the biggest tech companies. In the United States, the Justice Department recently filed an antitrust case against Google. The European Union has issued antitrust violations and enacted stiffer data-protection laws. The Australian government is pushing new rules to make Google and Facebook pay for certain content.

But many question whether the tactics are adequate, particularly if a lengthy enforcement and legal process slows down action against the fast-moving and deep-pocketed companies.

On Tuesday, Britain’s top antitrust regulator recommended a new approach. The Competition and Markets Authority released recommendations for creating a new regulator called the Digital Markets Unit that will focus on the biggest technology platforms. The regulator would be able to fine companies up to 10 percent of global revenue.

The idea of creating a tech industry regulator has gained momentum among academics and policymakers around the world. The aim is to treat giants like Amazon, Apple, Facebook, Google, and Microsoft more like the biggest companies in banking and health care — with dedicated regulators that have the expertise in the subject matter to serve as a watchdog and act quickly to address wrongdoing, akin to the Securities and Exchange Commission and the Food and Drug Administration.

Britain is perhaps the furthest along. The new regulator would be responsible for enforcing a legally binding code of conduct intended to prevent the biggest companies from using their dominance to exploit consumers and business, or to box out emerging competitors. Officials said only companies of a certain size would fall under the rules, which would be tailored to specific types of businesses. Google and Facebook may face certain restrictions related to digital advertising, while Amazon would have others related to e-commerce.

To improve competition, the regulator could force companies to share certain data with rivals, and it would review acquisitions.

The proposals build on recommendations made by a British panel of experts last year and are part of a process by the government to enact regulations for the digital economy by next year. Britain is preparing to leave the European Union, which next week will release its own draft laws to increase oversight of the tech industry across the 27-nation bloc.

British authorities have raised specific concerns about the digital advertising market dominated by Google and Facebook. In July, the Competition and Markets Authority published a 437-page investigation that concluded the two companies have such scale and unmatched access to user data that “potential rivals can no longer compete on equal terms.”

Goldman Sachs has reached a deal to buy out the minority partner in its Chinese securities joint venture, which could make it the first global bank to assume full ownership of its securities business in mainland China since the Communist Party took control of foreign-owned enterprises in the country in the 1950s.

In a memo to employees on Tuesday, the Wall Street bank said it had reached a definitive agreement to buy a 49 percent stake in Goldman Sachs Gao Hua still held by its local partner, Beijing Gao Hua Securities. Goldman Sachs did not disclose a price for the transaction.

The deal follows a pledge by Chinese leaders in 2017, amid worsening trade relations with the United States, to relax or remove limits on foreign bank ownership. The move was part of an unsuccessful effort by China to enlist Wall Street in heading off President Trump’s plans to impose tariffs on Chinese goods.

Goldman Sachs could be the first to take full control of its China securities business, depending on regulatory approval and how quickly the deal is completed.

JP Morgan Chase already has full ownership of its futures business in China, but still has a joint venture for other activities on the mainland. Other investment banks, like JP Morgan Chase, Morgan Stanley, UBS and Nomura, are in various stages of raising their stakes in their Chinese securities operations.

Commercial banks, by contrast, have avoided raising their stakes in commercial banking operations in mainland China above 25 percent. Doing so would subject those operations to further global banking regulations.

Goldman Sachs had announced on March 27 that it had obtained regulatory approval to raise its stake in Goldman Sachs Gao Hua from 33 percent to 51 percent. Tuesday’s memo was reported earlier by The Wall Street Journal.

With movie theaters largely shut across the United States, traditional movie companies like Warner Bros. are being forced to evolve.Credit…Aaron P/Bauer-Griffin, via Getty

Last week, when Jason Kilar, WarnerMedia’s chief executive, announced that 17 more Warner Bros. movies would each roll out on HBO Max and in theaters simultaneously. To prevent the news of the 17-movie shift from leaking (and to make the move speedily rather than get mired in the expected blowback), WarnerMedia kept the major agencies and talent management companies in the dark until roughly 90 minutes before issuing a news release, report Brooks Barnes and Nicole Sperling.

The surprise move left agencies on a war footing. Representatives for major Warner Bros. Talk of a Warner Bros. boycott began circulating inside the Directors Guild of America. A partner at one talent agency spent part of the weekend meeting with litigators. Some people started to angrily refer to the studio as Former Bros.

The 97-year-old studio, the ancestral home of Humphrey Bogart (“Casablanca”) and Bette Davis (“Now, Voyager”), suddenly finds itself at the uncomfortable center of a Hollywood that is changing at light speed. Even before the pandemic, streaming services like Netflix, Apple TV+ and Amazon Prime Video were upending how movies get seen and their creators are compensated. Now, with theaters struggling because of the coronavirus and the public largely stuck at home, even traditional film companies are being forced to evolve.

It’s not that all actors and directors are against streaming. Plenty of big names are making movies for Netflix. But last week’s move by Warner Bros. raised fundamental financial questions. If old-line studios are no longer trying to maximize the box office for each film but instead shifting to a hybrid model where success is judged partly by ticket sales and partly by the number of streaming subscriptions sold, what does that mean for talent pay packages?

How studios compensate A-list actors, directors, writers and producers is complicated, with contracts negotiated film by film and person by person. But it boils down to two checks. One is guaranteed (a large upfront fee) and one is a gamble: a portion of ticket sales after the studio has recouped its costs.

If a film flops, the second payday never comes. If a film is a hit, as is often the case with superheroes and other fantasy stories, the “back end” pay can add up to wheelbarrows full of cash.

A garage at the Aurora office in Palo Alto, Calif.Credit…Jason Henry for The New York Times

Uber, which spent hundreds of millions of dollars on a self-driving car project that executives once believed was a key to becoming profitable, is handing the autonomous vehicle effort over to a Silicon Valley start-up, the companies said on Monday.

Uber will also invest $400 million in the start-up, called Aurora, so it is essentially paying the company to take over the autonomous car operation, which had become a financial and legal headache. Uber is likely to license whatever technology Aurora manages to create.

The deal amounts to a fire-sale end to a high-profile but star-crossed effort to replace Uber’s human drivers with machines that could drive on their own. It is also indicative of the challenges facing other autonomous vehicle projects, which have received billions in investments from Silicon Valley and automakers but have not produced the fleets of robotic vehicles some thought would be on the streets by now.

Aurora’s chief executive, Chris Urmson, said Aurora’s first product will not be a robot taxi that could help with Uber’s ride-hailing business. Instead, it will likely be a self-driving truck, which Mr. Urmson believes has a better chance of success in the near term because long-haul truck driving on highways is more predictable and does not involve passengers.

In a statement, the Uber chief executive, Dara Khosrowshahi, said he was looking forward to bringing Aurora technology to market “in the years ahead.” Uber declined to comment further on the agreement.

  • Rashida Jones, a senior vice president for news at MSNBC and NBC News, will become the first Black woman to take charge of a major television news network. Her promotion, announced by Cesar Conde, the chairman of NBCUniversal News Group, is another big shake-up in the network’s management ranks. She will succeed Phil Griffin, the MSNBC president whose left-leaning shows yielded big ratings in the Trump years and minted media brands like “The Rachel Maddow Show” and “Morning Joe,” will depart on Feb. 1 after a 12-year tenure, the network said on Monday.

  • The Japanese advertising giant Dentsu Group plans to cut roughly 6,000 jobs as it grapples with the effects of the coronavirus pandemic. In a securities filing in Tokyo on Monday, Dentsu laid out details of its restructuring strategy, which will cost 88 billion yen (about $850 million) to carry out over two years and includes trimming its 48,000-person international work force by 12.5 percent. The timeline will vary by location, the company said.

Patrick Gaspard, a former aide to President Barack Obama, U.S. ambassador to South Africa and executive director of the Democratic National Committee, has emerged as the leading candidate to be nominated as labor secretary under President-elect Joseph R. Biden Jr., according to people with knowledge of the discussions.

Mr. Gaspard announced last week that he would step down as the head of the Open Society Foundations, founded by the liberal megadonor George Soros, at the end of the year, fueling speculation in Washington that he was poised to join the incoming administration. He has a background in labor organizing, including a senior leadership position for the Service Employees International Union, which he held before joining the Obama administration.

His potential nomination would give Mr. Biden, who calls himself a “union guy,” a labor secretary with union roots. He would also add to the list of Black cabinet appointees, a key goal of Mr. Biden’s transition team as it seeks to fulfill Mr. Biden’s campaign promise of diversity in the top leadership of his administration.

Born in the Democratic Republic of Congo to Haitian parents, Mr. Gaspard immigrated to the United States in early childhood, grew up in New York and attended Columbia University before leaving to work on Jesse Jackson’s 1988 presidential campaign. He worked for years in New York City politics and on Howard Dean’s 2004 Democratic presidential bid, and he was an aide to former Mayor David Dinkins. After Mr. Dinkins died last month, Mr. Gaspard wrote on Twitter, “He taught me that you don’t need to be loud to be strong.”

Mr. Gaspard worked for years as an organizer and rose through the Service Employees International Union to become its national political director before joining Mr. Obama’s 2008 presidential campaign. In the Obama White House, Mr. Gaspard served as director of political affairs, before helming the Democratic National Committee and being confirmed as Mr. Obama’s ambassador to South Africa.

Allies of Senator Bernie Sanders, independent of Vermont and Mr. Biden’s chief rival for the Democratic nomination this year, had pushed hard for Mr. Sanders to be selected as labor secretary. But Mr. Biden’s short list for the job does not appear to include Mr. Sanders.

Categories
World News

U.Ok. Tackles Big Vaccine Rollout After Botched Covid Response

U.K. Tackles Giant Vaccine Rollout After Botched Covid Response

LONDON – In Bristol, a sports stadium is being converted into a makeshift clinic to carry out vaccinations, as is a racetrack outside London. Village houses, libraries, and parking lots across the country are also rapidly becoming makeshift vaccination centers, with the government seeking advice from military planners.

As the UK prepares to begin rolling out a coronavirus vaccine on Tuesday, it is facing the greatest logistical challenge the country’s healthcare system has ever faced: vaccinating tens of millions of people against coronavirus in just a few months. At the same time, law enforcement agencies are grappling with a number of potential security threats to the vaccination campaign.

Healthcare retirees are being sought for help while the National Health Service recruits tens of thousands of first aid workers and other workers to administer the shot as the vaccine becomes more and more available.

“I think all people who can help should put their hands up,” said Sarah Wollaston, who worked as a doctor before serving in Parliament until recently. She has just completed part of an online refresher course to qualify for the vaccine launch.

“Physically, it’s very easy to give someone a vaccine,” she said. “The challenge is the logistics.”

As industry experts and health officials grapple with this, law enforcement officers and cyber experts face an equally pressing challenge regarding the potential security threats associated with such a high-demand product.

“It’s the world’s most precious commodity right now,” said Lisa Forte, a former UK counterintelligence officer and partner at Red Goat, a cybersecurity company. “This will of course attract highly skilled cyber criminals, criminal groups and state actors.”

Europol warned that organized crime groups could crack down on trucks with vaccines against theft and kidnapping, and Interpol last week warned of a “rush of all kinds of criminal activity related to the COVID-19 vaccine,” which it calls “liquid gold” has designated. ”

From the factory to hospitals and other locations, the Pfizer vaccine – because it must be stored at around minus 70 degrees Celsius – is acutely susceptible to sabotage in addition to theft.

“With the vaccine, the two biggest risks are maintaining the cold chain and being intercepted by public or private actors,” said Sarah Rathke, an attorney at Squire Patton Boggs, who specializes in supply chain litigation.

“It is possibly the toughest supply chain challenge in recent history as there is not much time to prepare,” added Rathke.

Cyberattacks can reveal a wealth of information about the vaccines that can be exploited by state actors and criminal gangs, experts say.

Last week, IBM announced it had discovered a number of cyberattacks against companies involved in spreading coronavirus vaccines around the world in September. IBM said the attackers, whose identities could not be established, tried to learn how the vaccines were stored and dispensed.

“We targeted petrochemical companies because they are essential for making dry ice to store the vaccine,” said Claire Zaboeva, a senior cyber threat analyst at IBM’s Security X-Force.

Ms. Zaboeva added that state actors or even terrorist groups could try to disrupt supplies as nations compete to be the first to administer the vaccine. “Making a lot of vaccine doses spoiled and useless would be a pretty devastating attack,” she said.

While security agencies address these concerns, the UK health service will face the daunting problem of managing a mass vaccination program that reaches the population farther and faster than any other public health work in living memory.

A charity, St. John Ambulance, wants to train up to 30,000 vaccines and others in vaccination centers.

“Introducing a vaccine to tens of millions of people will be a monumental task as we seek to save lives and hopefully get back to our normal way of life,” said Ian Hudspeth, chairman of the Community Wellbeing Board for the Local Government, which represents local communities .

Success is hardly guaranteed as the UK achieved few logistical results during the Covid-19 crisis. In the early stages of the pandemic, hospitals chronically lacked basic protective equipment such as masks and gloves, putting some workers at risk of infection.

Since then, the government has made efforts to put in place a testing and tracing system, even though the much-criticized project was valued at around $ 16 billion.

Pfizer’s problems in sourcing raw materials alone could mean the number of vaccine doses promised for delivery to the UK this year may be cut by half to five million. And there is a potential bottleneck in the production of dry ice that is needed to package and ship the vaccine.

However, experts are cautiously optimistic that the vaccine rollout will go better than the government’s earlier efforts to fight the pandemic, as it is handled under the umbrella of the National Health Service, which has extensive experience organizing mass vaccinations such as annual flu shots .

“It won’t be without its problems because of its size and logistics – I would be amazed if nothing went wrong anywhere in six months,” said Helen Buckingham, director of strategy and operations at the Nuffield Trust, a health research institute.

However, the concept of mass vaccination is well known, she added, “and overall people go to great lengths to do this work.”

Vaccines are sold in three different places: hospitals; Medical practices and clinics; and temporary vaccination centers that are still in preparation, including transit sites, sports stadiums, and public buildings. General practitioners, who will shoulder much of the burden, can draw on their experience of delivering at least 15 million flu vaccinations each year.

However, the coronavirus vaccination will be different for several reasons. In addition to the vaccine against Pfizer and BioNTech, the UK is likely to get at least two more approved, one from Moderna and one from AstraZeneca and the University of Oxford. But when and where everyone will be available is unclear.

Martin Marshall, Chairman of the Council of the Royal College of General Practitioners, notes that the refrigeration requirements, especially for the Pfizer and Moderna vaccines, are a complication that doctors do not have to deal with flu shots. Both require a second injection after a few weeks, which can be an administrative nightmare.

“We’re pretty used to running large vaccination programs, but of course nobody has had to do one unless vaccinations are done in pre-filled syringes,” said Marshall.

According to experts, doctor’s offices and other makeshift clinics could come into play more if the AstraZeneca vaccine is approved. Not only does it cost a lot less, but it can also be stored with normal refrigeration.

Then there are concerns that the average Briton, let alone anti-vaccination campaigners, will be reluctant to take the Pfizer and Moderna vaccines, which are based on relatively untested technology.

Priority is given to those with the highest risk and the oldest Brits. Therefore, a system is also needed to call the right people for appointments at certain times and to do this again three weeks later for the second shot.

Early plans to vaccinate nursing home residents have been postponed because of the deceptively annoying question of how to dismantle Pfizer-supplied 975-dose batches and get them safely into those facilities. And it is unclear when – and in what quantities – other vaccines will be available.

All of this has to happen at a time when the health sector is in acute strain, its staff is overwhelmed after months of relentless pressure and during a winter season when people are generally more susceptible to disease.

Even so, Mr. Marshall is confident that the introduction of the vaccine can be successful.

“I think we can do this job if we work across the NHS and show some flexibility,” he said. “It plays with the strength of the NHS, a centralized, organized and managed system – and it also plays with our values.”

Categories
World News

Inventory futures fall as merchants weigh stimulus prospects and surging Covid circumstances

Stock futures fall as traders weigh stimulus prospects and surging Covid cases

Stock futures fell early Tuesday as traders watched negotiations on additional fiscal stimulus as the U.S. coronavirus case number continued to rise.

Dow Jones Industrial Average futures implied an opening loss of around 150 points. S&P 500 futures and Nasdaq 100 futures were also lower.

Tesla shares fell from a record high after the electric vehicle maker announced it was selling up to $ 5 billion worth of shares.

Republican and Democratic leaders said Monday that Congress is trying to extend state funding for another week to try to reach an agreement on the new Covid-19 aid. The news came after a bipartisan group of senators tabled a $ 908 billion stimulus proposal last week.

“The news from DC that talks on fiscal stimulus have resumed is also a positive development (although this might all be hats, not beasts, until a deal actually gets past the president’s desk),” wrote Willie Delwiche, investment strategist at Baird. “These headlines come at a critical time as we remain in a challenging time from both a health and an economic perspective.”

Calls for a new relief bill to be enforced before the end of the year has risen recently as U.S. employment growth continues to slow and the number of Covid-19 cases continues to rise.

According to the Johns Hopkins University, more than 14.8 million coronavirus cases have been confirmed in the United States. The country’s daily infection rate is also at an all-time high, averaging seven days.

This recent surge in Covid-19 cases has prompted several states and cities to introduce stricter social distancing measures. New York Governor Andrew Cuomo said Monday that New York City could lose indoor dining next week, adding that stricter restrictions would be imposed if hospitals reach a critical point.

“You cannot overwhelm the hospital system,” said Cuomo. “Overpowering the hospital system means people die on a stretcher in a hallway.”

The spike in Covid infections combined with uncertainty about additional tax subsidies kept the Dow and S&P 500 off record levels on Monday. The Dow slipped nearly 150 points, or 0.5%. The S&P 500 retreated 0.2%. However, the Nasdaq Composite rose 0.5% to a new record as traders sold value stocks in favor of soaring growth names.

The iShares Russell 1000 Value ETF (IWD) was down 0.6%. Its growth counterpart, the iShares Russell 1000 Growth ETF (IMF), rose 0.4%.

Subscribe to CNBC PRO for exclusive insights and analysis as well as live business day programs from around the world.

Categories
Health

The UK Simply Accepted the Pfizer Covid Vaccine. What Occurs Subsequent?

The UK Just Approved the Pfizer Covid Vaccine. What Happens Next?

LONDON – The first rigorously tested coronavirus vaccine was given the green light for use in the UK on Wednesday. The vaccine doses of the American pharmaceutical giant Pfizer and a small German company, BioNTech, will be injected from next week, the government said.

When the UK jumped before the United States to allow mass vaccination, it put pressure on American drug regulators, who were called to the White House by President Trump’s chief of staff on Tuesday to explain why they were unwilling to do the same.

The two countries study vaccines differently.

Rather than accepting the vaccine manufacturers’ results, American regulators are carefully re-analyzing the raw data from the studies to validate the results, considering what regulators described as thousands of pages of documents. Dr. Stephen Hahn, the commissioner for the Food and Drug Administration, said Tuesday that the FDA is “one of the few regulators in the world actually looking at the raw data.”

Regulators in the UK and other European countries rely more on in-house analysis. Instead of sifting through the raw study data and figuring out the numbers themselves, regulators often examine a drug manufacturer’s reports and, if there are no anomalies, justify their decisions in company-provided documents.

Whether the UK was rushing to approve a vaccine or whether the US was wasting valuable time as the virus kills around 1,500 Americans a day sparked a lively debate among scientists and industry experts on Wednesday. European regulators said UK approval is so limited that it only applies to certain lots of the vaccine, a claim Pfizer denied and which UK officials failed to address.

Dr. Paul Offit, a professor at the University of Pennsylvania and a member of the FDA’s Vaccine Advisory Council, said in an interview Wednesday that regulators’ success in getting vaccines approved while minimizing unforeseen errors justifies a rigorous approach.

“It is remarkable that we were able to access viruses with so few casualties,” he said, adding that American regulators were only days away from completing their own review.

The FDA has scheduled a meeting of an independent panel of experts on December 10th to review Pfizer’s vaccine. UK regulators also seek opinions from a technical committee, but this group has the flexibility to review and meet data as needed so that it can be implemented more quickly.

“In the UK, they could just say, ‘We have the data, we have the meeting,” said Stephen Evans, Professor of Pharmacoepidemiology at the London School of Hygiene & Tropical Medicine.

To speed up the process, the UK Medicines and Health Products regulator had their experts review vaccine dates as soon as they were available, and separate teams worked in parallel on different parts of the process rather than waiting for another to complete.

“If you are climbing a mountain, prepare,” said Dr. June Raine, executive director of the agency, on Wednesday. “We started this in June.”

When the first results came in on November 10, she said, “We were in base camp.” And later she said, “When we got the final analysis, we were ready for the final sprint.”

The UK has left the European Union’s regulatory orbit to get early approval for a vaccine as the bloc gives countries emergency powers in the event of a pandemic. Once the UK separates from the European Union on December 31, those vaccine-only powers will become permanent.

The countries remaining in the European Union are waiting for their regulator, the European Medicines Agency, to approve a vaccine. Like the FDA, the European regulator has scheduled a meeting on December 29th to consult outside experts and provide an opinion on the Pfizer vaccine.

The agency’s task is made more difficult by its obligation to seek the views of all 27 EU countries. This process was sped up during the pandemic, but it will be a few more days for countries to weigh in after the meeting, which will likely delay vaccinations until early January.

Pfizer plans to ship 800,000 cans to the UK in the coming days. As of Tuesday evening, these cans were being prepared for shipment at a factory in Puurs, Belgium, BioNTech said.

The cans are packaged in cardboard boxes, using dry ice to keep them at the south pole-like temperatures they need, before being placed on trucks or planes and taken to the UK. They will arrive at state distribution warehouses over the weekend, Pfizer said on Wednesday.

UK hospitals have already started emailing staff to inform them of vaccination schedules. A London hospital system states that the first doses are given on Monday at 7 a.m. The UK has placed pre-orders for 40 million doses of the Pfizer vaccine, but most of them are expected to be administered over the next year. Each patient needs two, one month apart.

A government advisory council released its list of vaccine priority groups on Wednesday. At the top of the list are residents and workers of nursing homes, followed by people over the age of 80 and health and social care workers.

In practice, however, government officials said Wednesday that they would initially limit vaccinations to a network of 50 hospitals due to the difficulty of storing and shipping the Pfizer vaccine. As a result, nurses, doctors, nursing home staff, and people 80+ who had made appointments would come first for the vaccine before residents of the nursing home.

Pfizer has said the vaccine can survive for five days in a regular refrigerator. However, the UK’s National Health Service has yet to consider issues such as staffing at locations outside the hospital and transportation difficulties within the country to decide how to administer the vaccine.

The National Health Service has around 150,000 doctors and more than 330,000 nurses and midwives.

The British decision will not in itself bring vaccinations any closer. However, Pfizer executives said Wednesday they had heard from other countries that they wanted to speed up their own approval processes in the face of UK approval.

American regulators, despite months of pressure from Mr. Trump, have claimed that they will follow their plan and review Pfizer’s vaccine to FDA standards.

The US has pre-ordered 100 million doses of the Pfizer vaccine. Most of the supply will come from a separate factory in Kalamazoo, Michigan. Still, many questions remain unanswered as to how vaccine manufacturers like Pfizer will fulfill the orders of wealthier nations that have pre-sourced supplies.